Evolutionary Tree Capital Management LLC Has $3.19 Million Position in Ascendis Pharma A/S $ASND

Evolutionary Tree Capital Management LLC cut its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 10.7% in the second quarter, Holdings Channel reports. The fund owned 18,454 shares of the biotechnology company’s stock after selling 2,202 shares during the period. Ascendis Pharma A/S comprises approximately 3.4% of Evolutionary Tree Capital Management LLC’s holdings, making the stock its 14th biggest position. Evolutionary Tree Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $3,185,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. T. Rowe Price Investment Management Inc. lifted its holdings in Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company’s stock valued at $475,970,000 after purchasing an additional 328,278 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Ascendis Pharma A/S during the first quarter worth about $51,029,000. RA Capital Management L.P. increased its holdings in shares of Ascendis Pharma A/S by 1.7% during the first quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock worth $1,602,474,000 after buying an additional 168,752 shares in the last quarter. Braidwell LP acquired a new stake in shares of Ascendis Pharma A/S during the first quarter worth approximately $16,632,000. Finally, American Century Companies Inc. raised its stake in shares of Ascendis Pharma A/S by 14.9% in the second quarter. American Century Companies Inc. now owns 530,809 shares of the biotechnology company’s stock valued at $91,619,000 after acquiring an additional 68,638 shares during the last quarter.

Ascendis Pharma A/S Trading Up 1.2%

Shares of NASDAQ:ASND opened at $212.44 on Friday. Ascendis Pharma A/S has a 1-year low of $118.03 and a 1-year high of $223.18. The stock has a market capitalization of $13.11 billion, a P/E ratio of -41.17 and a beta of 0.44. The business has a 50-day moving average price of $204.38 and a two-hundred day moving average price of $187.90.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The firm had revenue of $290.24 million for the quarter, compared to the consensus estimate of $246.91 million. As a group, equities analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their price objective on Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Wall Street Zen lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Royal Bank Of Canada lifted their price target on Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Finally, Stifel Nicolaus upped their price target on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $256.60.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.